Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

被引：16

作者：

Andre, F. ^{[1
]}

Nadal, J. C. ^{[2
]}

Denys, H. ^{[3
]}

Goel, S. ^{[4
]}

Litchfield, L. M. ^{[5
]}

Appiah, A. ^{[5
]}

Chen, Y. ^{[5
]}

Tolaney, S. M. ^{[6
]}

机构：

[1] Gustave Roussy Canc Campus, Dept Med Oncol, Breast Canc Unit, Villejuif, France

[2] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina

[3] Univ Ziekenhuis Gent, Dept Med Oncol, Ghent, Belgium

[4] Peter MacCallum Canc Ctr, Dept Canc Res, Melbourne, Vic, Australia

[5] Eli Lilly & Co Global Headquarters, Oncol, Indianapolis, IN USA

[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1016/j.annonc.2022.08.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA18

引用

页码：S1386 / S1387

页数：2